Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: Stability, pharmacokinetic and therapeutic evaluation

Jun Jen Liu, Ruey Long Hong, Wen Fang Cheng, Keelung Hong, Fu Hsiung Chang, Yun Long Tseng

研究成果: 雜誌貢獻文章

34 引文 (Scopus)

摘要

Topotecan (TPT), a topoisomerase I inhibitor, is presently undergoing clinical evaluation worldwide. Previous studies have shown that entrapping TPT within multi-lamellar vesicle liposome can stabilize the lactone moiety, which is structurally important for biological activity. However, low drug:lipid ratios due to the amphipathic character and small entrapment volume in the unilamellar vesicle limits the development of pharmaceutically acceptable liposomal formulation. With an aim to improve on this drawback, we herein describe a method that utilizes the ammonium sulfate gradient to entrap TPT into liposomes. By this method, the encapsulation efficiency was over 90% and a drug:lipid molar ratio as high as 1:5.4 was reached. In comparison with free drug, liposome-encapsulated TPT is more stable in physiological conditions and shows higher in vitro cytotoxicity. Because of increased blood circulation time, the initial plasma concentration and area under the plasma concentration of liposomal drugs were 14 and 40 times, respectively, of those of free drug. Furthermore, liposome encapsulation enhanced the antitumor activity of TPT in syngeneic murine C-26 and human HTB-9 xenograft models in vivo. At a dose of 5 mg/kg, the tumor growth delay of liposomal formulation was significantly than that of free TPT. Based on these results, we believe that this liposomal TPT formulation is worthy of further clinical study.

原文英語
頁(從 - 到)709-717
頁數9
期刊Anti-Cancer Drugs
13
發行號7
DOIs
出版狀態已發佈 - 八月 2002
對外發佈Yes

指紋

Topotecan
Ammonium Sulfate
Pharmacokinetics
Liposomes
Pharmaceutical Preparations
Therapeutics
Blood Circulation Time
Topoisomerase I Inhibitors
Lipids
Unilamellar Liposomes
Lactones
Heterografts
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

引用此文

Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient : Stability, pharmacokinetic and therapeutic evaluation. / Liu, Jun Jen; Hong, Ruey Long; Cheng, Wen Fang; Hong, Keelung; Chang, Fu Hsiung; Tseng, Yun Long.

於: Anti-Cancer Drugs, 卷 13, 編號 7, 08.2002, p. 709-717.

研究成果: 雜誌貢獻文章

Liu, Jun Jen ; Hong, Ruey Long ; Cheng, Wen Fang ; Hong, Keelung ; Chang, Fu Hsiung ; Tseng, Yun Long. / Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient : Stability, pharmacokinetic and therapeutic evaluation. 於: Anti-Cancer Drugs. 2002 ; 卷 13, 編號 7. 頁 709-717.
@article{5b175faee77a443b881bf01e27ed98c1,
title = "Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: Stability, pharmacokinetic and therapeutic evaluation",
abstract = "Topotecan (TPT), a topoisomerase I inhibitor, is presently undergoing clinical evaluation worldwide. Previous studies have shown that entrapping TPT within multi-lamellar vesicle liposome can stabilize the lactone moiety, which is structurally important for biological activity. However, low drug:lipid ratios due to the amphipathic character and small entrapment volume in the unilamellar vesicle limits the development of pharmaceutically acceptable liposomal formulation. With an aim to improve on this drawback, we herein describe a method that utilizes the ammonium sulfate gradient to entrap TPT into liposomes. By this method, the encapsulation efficiency was over 90{\%} and a drug:lipid molar ratio as high as 1:5.4 was reached. In comparison with free drug, liposome-encapsulated TPT is more stable in physiological conditions and shows higher in vitro cytotoxicity. Because of increased blood circulation time, the initial plasma concentration and area under the plasma concentration of liposomal drugs were 14 and 40 times, respectively, of those of free drug. Furthermore, liposome encapsulation enhanced the antitumor activity of TPT in syngeneic murine C-26 and human HTB-9 xenograft models in vivo. At a dose of 5 mg/kg, the tumor growth delay of liposomal formulation was significantly than that of free TPT. Based on these results, we believe that this liposomal TPT formulation is worthy of further clinical study.",
keywords = "Ammonium sulfate gradient, Drug delivery system, Liposome, Topotecan",
author = "Liu, {Jun Jen} and Hong, {Ruey Long} and Cheng, {Wen Fang} and Keelung Hong and Chang, {Fu Hsiung} and Tseng, {Yun Long}",
year = "2002",
month = "8",
doi = "10.1097/00001813-200208000-00005",
language = "English",
volume = "13",
pages = "709--717",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient

T2 - Stability, pharmacokinetic and therapeutic evaluation

AU - Liu, Jun Jen

AU - Hong, Ruey Long

AU - Cheng, Wen Fang

AU - Hong, Keelung

AU - Chang, Fu Hsiung

AU - Tseng, Yun Long

PY - 2002/8

Y1 - 2002/8

N2 - Topotecan (TPT), a topoisomerase I inhibitor, is presently undergoing clinical evaluation worldwide. Previous studies have shown that entrapping TPT within multi-lamellar vesicle liposome can stabilize the lactone moiety, which is structurally important for biological activity. However, low drug:lipid ratios due to the amphipathic character and small entrapment volume in the unilamellar vesicle limits the development of pharmaceutically acceptable liposomal formulation. With an aim to improve on this drawback, we herein describe a method that utilizes the ammonium sulfate gradient to entrap TPT into liposomes. By this method, the encapsulation efficiency was over 90% and a drug:lipid molar ratio as high as 1:5.4 was reached. In comparison with free drug, liposome-encapsulated TPT is more stable in physiological conditions and shows higher in vitro cytotoxicity. Because of increased blood circulation time, the initial plasma concentration and area under the plasma concentration of liposomal drugs were 14 and 40 times, respectively, of those of free drug. Furthermore, liposome encapsulation enhanced the antitumor activity of TPT in syngeneic murine C-26 and human HTB-9 xenograft models in vivo. At a dose of 5 mg/kg, the tumor growth delay of liposomal formulation was significantly than that of free TPT. Based on these results, we believe that this liposomal TPT formulation is worthy of further clinical study.

AB - Topotecan (TPT), a topoisomerase I inhibitor, is presently undergoing clinical evaluation worldwide. Previous studies have shown that entrapping TPT within multi-lamellar vesicle liposome can stabilize the lactone moiety, which is structurally important for biological activity. However, low drug:lipid ratios due to the amphipathic character and small entrapment volume in the unilamellar vesicle limits the development of pharmaceutically acceptable liposomal formulation. With an aim to improve on this drawback, we herein describe a method that utilizes the ammonium sulfate gradient to entrap TPT into liposomes. By this method, the encapsulation efficiency was over 90% and a drug:lipid molar ratio as high as 1:5.4 was reached. In comparison with free drug, liposome-encapsulated TPT is more stable in physiological conditions and shows higher in vitro cytotoxicity. Because of increased blood circulation time, the initial plasma concentration and area under the plasma concentration of liposomal drugs were 14 and 40 times, respectively, of those of free drug. Furthermore, liposome encapsulation enhanced the antitumor activity of TPT in syngeneic murine C-26 and human HTB-9 xenograft models in vivo. At a dose of 5 mg/kg, the tumor growth delay of liposomal formulation was significantly than that of free TPT. Based on these results, we believe that this liposomal TPT formulation is worthy of further clinical study.

KW - Ammonium sulfate gradient

KW - Drug delivery system

KW - Liposome

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0036667944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036667944&partnerID=8YFLogxK

U2 - 10.1097/00001813-200208000-00005

DO - 10.1097/00001813-200208000-00005

M3 - Article

C2 - 12187327

AN - SCOPUS:0036667944

VL - 13

SP - 709

EP - 717

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 7

ER -